News & Publications

NEWS & PUBLICATIONS

Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.


Innovative in silico approach opens new avenues in drug discovery for the treatment of CNS disorders   Barcelona: Prous Institute for Biomedical Research is presenting the results of its work to construct a predictive computational system mimicking the different processes involved in neuroplasticity with the aim of identifying molecules with potential pharmacological activity.   ...


SYMMETRY® − an ensemble of computational tools and methods aiming to replicate all the processes through which new drugs are discovered, developed and approved – supports several strategies to discover new drugs. Here we describe modifying the chemical structures of natural products to improve their pharmacological efficacy and ADMET profiles as well as identifying new indications....


San Francisco, March 15, 2012 - Prous Institute for Biomedical Research and the FDA Center for Drug Evaluation and Research (CDER)  have found promising validation results for the predictive performance of mutagenicity models using Prous Institute's Symmetry® computational software and the FDA/NCTR Mold2 descriptor package. Prous Institute and the FDA/CDER are jointly presenting the...


San Francisco, March 14, 2012 - Prous Institute for Biomedical Research has reported encouraging statistically significant results for cross-validation and external validation of cytochrome P450 3A4 and 2D6 inhibitor models created using its BioEpisteme® predictive software. The findings are a result of an FDA-approved research collaboration and are being presented jointly with the FDA Center ...


Washington D.C., USA: The Food and Drug Administration's Center for Food Safety and Applied Nutrition(FDA/CFSAN) and Prous Institute for Biomedical Research (PIBR) will work jointly under a 5 year research collaboration agreement (RCA) to develop hypothesis based in silico predictive tools that are consistent with CFSAN's and FDA’s Critical Path Initiative.This research will benefit CFSAN, t...

Page 5 of 7First   Previous   1  2  3  4  [5]  6  7  Next   Last